<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Syniverse Holdings Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/syniverse-holdings-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Releases Encouraging Data on Zalbin</title>
		<link>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742</link>
		<comments>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742#comments</comments>
		<pubDate>Thu, 25 Mar 2010 22:45:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31742</guid>
		<description><![CDATA[Recently, Human Genome Sciences Inc. (HGSI) announced interim results on hepatitis C candidate Zalbin from a mid-stage study. The study evaluated the safety and efficacy of Zalbin. The results revealed that a monthly dose of Zalbin was as effective as a weekly dose of Roche’s (RHHBY) Pegasys (peginterferon alfa-2a), which is the current standard of care. The study combined Zalbin with ribavirin in 391 treatment-naive patients infected with genotypes 2 and 3 hepatitis C. Full results from the study are expected to be presented later in the year. The subjects enrolled for the mid-stage study were randomized in a 4:4:4:3 ratio into four treatment groups. Patients in three groups received Zalbin, administered once a month (900 mcg, 1200 mcg or 1500 mcg). Patients in the other group received Pegasys at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/25/hgsi-human-genome-sciences-releases-encouraging-data-on-zalbin/31742/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BUCY) Grading Management with Return on Equity &#8211; Screen of the Week</title>
		<link>http://www.stockbloghub.com/2009/10/21/bucy-grading-management-with-return-on-equity-screen-of-the-week/18352</link>
		<comments>http://www.stockbloghub.com/2009/10/21/bucy-grading-management-with-return-on-equity-screen-of-the-week/18352#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:19:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Farm & Construction Machinery]]></category>
		<category><![CDATA[Industrial Goods]]></category>
		<category><![CDATA[BUCY]]></category>
		<category><![CDATA[Bucyrus International Inc.]]></category>
		<category><![CDATA[Investors Bancorp Inc]]></category>
		<category><![CDATA[ISBC]]></category>
		<category><![CDATA[STE]]></category>
		<category><![CDATA[Steris Corporation]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Wolverine World Wide Inc.]]></category>
		<category><![CDATA[WWW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18352</guid>
		<description><![CDATA[This week I want to talk about Return on Equity. Return on Equity, or ROE, is a commonly used measure of management efficiency. It&#8217;s a favorite screening criterion of many money managers and investors Incorporatedluding myself, because it tells you how successful a company is at using its shareholders&#8217; capital. Moreover, companies with steadily increasing ROEs are generally better managed with attention being paid to the details. Criteria Defined Return on Equity shows how much profit a company is making on its shareholder equity. The formula for ROE is calculated as: Income / Average Shareholders Equity (past 12 months) The Income number for a company is listed on their Income Statement. Shareholders Equity is the difference between Total Assets and Total Liabilities, and is found on a company&#8217;s Balance Sheet. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/bucy-grading-management-with-return-on-equity-screen-of-the-week/18352/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SVR) Syniverse Holdings &#8211; Top-Rated Company in its Industry</title>
		<link>http://www.stockbloghub.com/2009/10/09/svr-syniverse-holdings-top-rated-company-in-its-industry/17303</link>
		<comments>http://www.stockbloghub.com/2009/10/09/svr-syniverse-holdings-top-rated-company-in-its-industry/17303#comments</comments>
		<pubDate>Fri, 09 Oct 2009 19:35:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Communication Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17303</guid>
		<description><![CDATA[Syniverse Holdings Inc. (SVR) shares have spiked on acquisition news and estimates are climbing. Company Description Syniverse provides technology to the wireless communications industry. The company&#8217;s products provide a seamless global network by integrating multiple carriers&#8217; networks. Leading the Pack Syniverse is the top rated company in its industry on Zacks.com. The company operates with a net profit margin of 15.5%, compared to the industry average 1.2%. Syniverse is returning 18.4% on equity, well above the 2.1% its peers normally generate. Additionally, Syniverse carries a debt-to-equity ratio of 0.9 times, a third of the industry average. Shares are also a solid value at just 11 times earnings in a sector that often sees bloated valuations. Making the Grade On Aug 5 Syniverse met analysts&#8217; expectations by reported net income of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/09/svr-syniverse-holdings-top-rated-company-in-its-industry/17303/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRSN) VeriSign Sells its Messaging Business</title>
		<link>http://www.stockbloghub.com/2009/08/27/vrsn-verisign-sells-its-messaging-business/13554</link>
		<comments>http://www.stockbloghub.com/2009/08/27/vrsn-verisign-sells-its-messaging-business/13554#comments</comments>
		<pubDate>Thu, 27 Aug 2009 20:14:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Internet Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[VeriSign Inc.]]></category>
		<category><![CDATA[VRSN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13554</guid>
		<description><![CDATA[VeriSign Inc. (VRSN) yesterday agreed to sell its messaging business to Syniverse Holdings Inc. (SVR) for $175 million. The transaction is subject to certain closing conditions and regulatory approvals. Headquartered in Mountain View, California, VeriSign provides essential Internet infrastructure services to companies, service providers and website owners. Tampa, Florida-based Syniverse provides wireless voice and data services for telecommunications companies worldwide. The company said that the deal will expand its mobile messaging capabilities and increase its global footprint through nearly 300 additional employees in the United States and Asia Pacific. The messaging business has had an annual revenue run-rate of approximately $140 million over the last 12 months. With this divestiture, VeriSign will be left with only one of its thirteen businesses to divest. From November 2007 to date, the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/vrsn-verisign-sells-its-messaging-business/13554/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

